Waldman Reid Alexander 4

What Happened

• Reid Waldman, a director of Achieve Life Sciences, was granted an award of 47,250 derivative shares (transaction code A) on May 29, 2026. The reported price is $0.00, indicating no cash was paid at grant; the instrument is a time-based equity award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-29; Filing date: 2026-06-02 (Form 4 accession 0002107415-26-000004).
• Type: Grant/Award of derivative securities (code A) — 47,250 shares; reported price $0.00.
• Vesting: Award vests in substantially equal monthly installments over 36 months beginning May 29, 2026, subject to continued service (per footnote).
• Shares owned after transaction: not disclosed in the supplied filing.
• Timeliness: filing shows the report date of June 2, 2026; no late-filing flag was provided in the materials reviewed.

Context

• This was a time-based equity grant to a director, not a market purchase or sale. Such awards are commonly used for director compensation and do not by themselves indicate buying or selling sentiment. The award will vest over time, so any future sales or exercises would be reported separately.